Researchers did this study to investigate the yearly change of real-world outcomes for BCVA after a 2-year clinical intervention for treatment-naïve DMO.

Retrospective analysis of aggregated, longitudinal medical records obtained from twenty-seven retina specialized institutions in Japan from Survey of Treatment for DMO database. A total of two thousand twenty-nine treatment-naïve centers involving DMO eyes of which the initial intervention.

Even though there was no change observed in the baseline BCVA by year, the 2-year improvement of BCVA increased and reached +6.5 letters in the latest term. There is little difference among starting years about proportions of eyes which BCVA gained >15 letters, in contrast to those which lost >15 letters were decreased by year. The ratio of eyes that maintained the socially acceptable vision of BCVA>20/40 increased and reached 59.0% in the latest term.

The study concluded that in recent years, treatment patterns for DMO have been gradually but certainly changed; as a result, better visual gain, suppression of worsened eyes, and better final BCVA have been obtained. Anti-VEGF therapy has become the first-line therapy, and its injection frequency has been increasing.